| Literature DB >> 29208050 |
Ching-Wen Huang1,2, Hsiang-Lin Tsai1,2,3,4, Yung-Sung Yeh2,5,6, Wei-Chih Su2,6, Ming-Yii Huang7, Chun-Ming Huang7, Yu-Tang Chang4,6,8, Jaw-Yuan Wang9,10,11,12,13,14,15.
Abstract
BACKGROUND: The robotic system has advantages of high-definition three-dimensional vision and articular instruments with high dexterity, allowing more precise dissection in the deep and narrow pelvic cavity.Entities:
Keywords: Circumferential resection margin; R0 resection; Rectal cancer; Robotic-assisted total mesorectal excision; Single-docking
Mesh:
Year: 2017 PMID: 29208050 PMCID: PMC5716256 DOI: 10.1186/s12893-017-0315-x
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1a Port positions during single docking with the five-port technique. b Port positions during single docking with the six-port technique
Baseline characteristics and perioperative outcomes of 95 patients with stage 0-III rectal cancer undergoing robotic-assisted total mesorectal excision
| Characteristic | |
|---|---|
| Age (years, median) (range) | 62 (28–88) |
| Gender | |
| Female | 35 (36.8%) |
| Male | 60 (63.2%) |
| Tumor distance from anal verge (cm) | |
| ≦ 5 (Lower) | 48 (50.5%) |
| 6–10 (Middle) | 30 (31.6%) |
| 11–15 (Upper) | 17 (17.9%) |
| Distance from anal verge (cm, median) (range) | 5.5 (1–15) |
| Pre-operation CCRT | |
| Yes | 75 (78.9%) |
| No | 20 (21.1%) |
| Pre-operation chemotherapy regimen | 75 |
| FOLFOX | 58 (77.3%) |
| Fluoropyrimidine-based | 17 (22.7%) |
| Time interval between radiotherapy completion and robotic surgery (day, median) (range) (75 patients undergoing pre-operation chemotherapy) | 82 (41–203) |
| ASA classification | |
| II | 52 (54.7%) |
| III | 43 (45.3%) |
| BMI kg/m2 (Median) (range) | 23.54 (17.20–34.02) |
| Procedure | |
| LAR | 59 (62.1%) |
| ISR | 32 (33.7%) (including 3 transabdominal ISR) |
| APR | 4 (4.2%) |
| Protective Diverting Colostomy | |
| Yes | 38 (40.0%) |
| No | 57 (60.0%) |
| Docking Time (min, median) (range) | 5 (3–22) |
| Console Time (min, median) (range) | 200 (130–435) |
| Operation Time (min, median) (range) | 325 (210–795) |
| Estimated blood loss (mL, Median) | 80 (15–1050) |
| Time of first flatus passage (day) (Median, range) | 2 (1–10) |
| Time of resuming soft diet (day) (Median, range) | 4 (2–15) |
| Postoperative hospital stay (day) (Median, range) | 6 (5–32) |
| Postoperative first day VAS pain score (Median, range) | 3 (1–8) |
APR abdominoperineal resection, AR anterior resection, ASA American Society of Anesthesiologists, BMI Body mass index, CCRT Concurrent chemoradiotherapy, ISR, intersphenteric resection, LAR low anterior resection, VAS visual analog scale
Postoperative complications in 95 patients with stage 0-III rectal cancer undergoing robotic-assisted total mesorectal excision
| Complications | Number (%) | Management |
|---|---|---|
| Post-operative bleeding | 1 (1.0%) | Laparotomy |
| Intra-abdominal infection/abscess | 3 (3.2%) | 2: conservative treatment |
| 1: CT-guided pig-tail drainage | ||
| Coloanal Anastomosis Stenosis | 4 (4.2%) | Colonoscopic dilation |
| Ileus | 1 (1.0%) | Conservative treatment |
| Anastomosis leakage | 5 (5.4%) | Loop transverse colostomy |
| Urethral injury | 1 (1.0%) | Conservative treatment |
| Pulmonary complication | 2 (2.1%) | Conservative treatment |
| Total | 17 (17.9%) |
Clinicopathologic characteristics and oncological outcomes of 95 patients with stage 0-III rectal cancer undergoing robotic-assisted total mesorectal excision
| Preoperative clinical staging | |
| Tumor depth | |
| T1 | 2 (2.1%) |
| T2 | 19 (20.0%) |
| T3 | 61 (64.2%) |
| T4 | 13 (13.7%) |
| Lymph Node metastasis | |
| N0 | 38 (40.0%) |
| N1 | 40 (42.1%) |
| N2 | 17 (17.9%) |
| AJCCa Stage (Clinical) | |
| I | 14 (14.7%) |
| II | 24 (25.3%) |
| III | 57 (60.0%) |
| Postoperative pathological outcomes | |
| Histology | |
| Well differentiation | 16 (16.9%) |
| Moderate differentiation | 76 (80.0%) |
| Poor differentiation | 3 (3.1%) |
| Tumor size | |
| < 5 cm | 85 (89.5%) |
| ≥ 5 cm | 10 (10.5%) |
| Tumor size (cm, mean ± SD) (range) | 2.46 ± 1.652 (0–8) |
| Tumor depth | |
| T0 | 29 (30.5%) |
| Tis | 1 (1.0%) |
| T1 | 14 (14.7%) |
| T2 | 20 (21.1%) |
| T3 | 28 (29.5%) |
| T4 | 3 (3.2%) |
| Lymph Node metastasis | |
| N0 | 73 (77.1%) |
| N1 | 19 (19.8%) |
| N2 | 3 (3.1%) |
| AJCC Stage (Pathologic) | |
| 0 | 27 (28.4%) |
| I | 27 (28.4%) |
| II | 19 (20.0%) |
| III | 22 (23.2%) |
| Tumor Regression Grade (75 patients with preoperative CCRT) | |
| 0 | 28 (37.3%) |
| 1 | 30 (40.0%) |
| 2 | 11 (14.7%) |
| 3 | 6 (8.0%) |
| Harvested Lymph Node (median) (range) | 9 (0–36) |
| Harvested Apical Node (median) (range) | 2 (0–15) |
| Distance of distal resection margin (cm, median) (range) | 2.30 (0.2–6.5) |
| Distance of circumferential resection margin (cm, median) (range) | 1.0 (0.2–3.5) |
| Distal resection margin | |
| Free | 94 (98.9%) |
| Positive | 1 (1.1%) |
| Circumferential resection margin | |
| Free | 93 (97.9%) |
| Positive | 2 (2.1%) |
| Resection Degree of Primary tumor | |
| R0 | 92 (96.8%) |
| R1 | 3 (3.2%) |
| Oncological outcomes | |
| Follow-up periods (months, median) (range) | 25.6 (6.6–52.2) |
| R0 resection | 91 |
| Locoregional recurrence | 5 (5.5%) |
| Distant metastasis | 10 (11.0%) |
| Liver + Lung | 1 (1.1%) |
| Lung | 5 (5.5%) |
| Liver | 2 (2.2%) |
| Chest Wall | 1 (1.1%) |
| Peritoneal carcinomatosis | 1 (1.1%) |
| R1 resection | 3 |
| Local recurrence | 1 (33.3%) |
| Lung | 1 (33.3%) |
| Peritoneum | 1 (33.3%) |
a AJCC American Joint Commission on Cancer
Fig. 2The Kaplan–Meier survival curves. a Disease-free survival. b Overall survival. c Locoreginal control rate. d Distant metastatsis control rate
Fig. 3Learning curves for robotic rectal surgery. a Console time, all patients. b Operation time, all patients
Comparison of clinical and perioperative outcomes by robotic-assisted TMEa
| Study | Country (year) | Operation type | Sample size | Lower rectum (%) | Preoperative CCRTb (%) | Conversion Rate (%) | Estimated blood loss (mL) | Overall complications (%) | Anastomostic leakage (%) | Rate of sphincter preservation (%) | DRMc (cm) | Positive CRMd (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Present study (Huang et al.) | Taiwan (2017) | Totally robotic (single-docking)g | 95([y]p Stage 0-III) | 50.5 | 78.9 | 0 | 80 (15–1050) | 17.69 | 5.4 | 95.8 | 2.3 (0.2–6.5.) | 2.1 |
| Baek et al. [ | Korea (2011) | Hybrid | 41 ([y]p Stage 0-III) | 36.6e | 80.5 | 7.3 | 200 (20–2000) | 22.0 | 7.3 | 85.4 | 3.6 (0.4–10) | 2.4 |
| Park et al. [ | Korea (2011) | Hybrid | 52 ([y]p Stage 0-III) | 60.4f | 23.1 | 0 | NA | 19.2 | 9.6 | 100 | 2.8 | 1.9 |
| Hellan et al. [ | USA (2015) | Totally robotic or Hybrid | 425 ([y]p Stage I-IV) | 31.3 | 51.3 | 5.9 | 119 ± 164 | 40.2 | 8.7 | NA | 3.0 ± 2.0 | 0.9 |
| Ahmed et al. [ | UK (2016) | Totally robotic (single-docking)h | 83 | NA | 21.7 | 0 | 10 (0–200) | 49 | 2 | 88.0 | 2.7 (0.4–8.0) | 3.6 |
| Hellan et al. [ | USA (2007) | Hybrid | 39 ([y]p Stage I-IV) | 53.9f | 84.6 | 2.6 | 200 (25–6000) | 12.1 | 84.6 | 2.65 (0.4–7.5) | 0 | |
| Luca et al. [ | Italy (2009) | Totally robotic (single-docking)g | 28 ([y]p Stage I-IV) | NA | 0 | 0 | 68 ± 138 (0–600) | NA | NA | 75.0 | 2.5 ± 1.3 (0.6–5.5) | 0 |
| Kim et al. [ | Korea (2016) | Totally robotic (single-docking)h | 33 ([y]p Stage 0-III) | NA | 100 | 6.1 | 232.0 ± 180.0 | 45.6 | NA | 93.9 | 2.2 ± 1.5 | 16.1 |
| Saklani et al. [ | Korea (2013) | Totally robotic (single-docking)h | 74 ([y]p Stage 0-III) | NA | 100 | 1.4 | 180 ± 28.1 (0–1100) | 16.2 | 5.4 | 97.3 | 1.7 ± 1.4 (0.1–6.0) | 4 |
| Pai et al. [ | USA (2015) | Dual docking or Hybrid | 101 ([y]p Stage 0-IV) | 28.7 | 74.3 | 4 | 190 ± 128 | 28.7 | 6.3 | 79.2 | 3.5 ± 2.7 (0.1–16.3) | 5 |
| Kim et al. [ | Korea (2016) | Totally robotic (single-docking)h | 60 ([y]p Stage 0-IV) | 56.7e | 36.7 | 0 | 74.2 ± 50 | 15 | 5 | 93.4 | 3.1 ± 1.7 | 11.7 |
| Feroci et al. [ | Italy (2016) | Totally robotic (single-docking)g | 53 ([y]p Stage 0-III) | NA | 49.1 | 3.8 | 60.8 (0–400) | 26.4 | 5.7 | 100 | 2.5 (0.5–10) | 0 |
| Cho et al. [ | Korea (2012) | Totally robotic (single-docking)h | 278 ([y]p Stage 0-III) | 24.8 | 32.7 | 0.4 | 179.0 ± 236.5 | 25.9 | 10.4 | 100 | 2.0 ± 1.4 | 5.0 |
| Yamaguchi et al. [ | Japan (2016) | Totally robotic (single-docking)g | 203 ([y]p Stage 0-IV) | 60.1f | 0.5 | 0 | 15.4 ± 26.4 | 9 | 1.5 | 95.1 | 2.8 ± 1.9 | NA |
| Park et al. [ | Korea (2015) | Hybrid | 133 ([y]p Stage I-III) | 24.8 | 11.3 | 0 | 77.6 ± 153.2 (0–700) | 19.7 | 4.5 | 100 | 2.75 ± 2.14 (1–14) | 6.8 |
| Ghezzi et al. [ | Brazil/Italy (2014) | Totally robotic (single-docking)g | 65 ([y]p Stage 0-III) | 100f | 72.3 | 1.5 | 0 (0–175) | 41.5 | 7.1 | 86.2 | 2.7 (1.6–4.4) | 0 |
| Ramji et al. [ | Canada (2016) | Hybrid | 26 | NA | 58 | 12 | 296 ± 155 | 42 | 8 | 85 | 2.96 ± 2.05 | 0 |
| Hara et al. [ | Korea (2014) | Totally robotic (single-docking)h | 200 ([y]p Stage 0-IV) | 56.5 | 27.5 | 0 | 190 (0–1500) | 38.5 | 9.5 | 93.5 | 1.8 (0–22.0) | 1.5 |
| Bail et al. [ | Korea (2013) | Totally robotic (single-docking)h | 370 ([y]p Stage 0-IV) | 26.8 | 21.1 | 0.8 | 245.7 ± 222.1 (10.0–1300.0) | 24.6 | 7.7 | 99.2 | 2.6 ± 1.4 | 6.9 |
NA not avaliable
aTME total mesorectal excision
bCCRT concurrent chemoradiotherapy
cCRM circumferential resection margin
dDRM distal resection margin
e< 7cm
fExtraperitoneal
gwithout moving both the robotic surgical cart and repositioning robotic arms
hwithout moving the robotic surgical cart, but repositioning robotic arms
Comparison of short-term oncological outcomes by robotic-assisted TMEa
| Study | Country (year) | Local recurrence (%) | Distant metastasis (%) | Disease-free survival | Overall survival |
|---|---|---|---|---|---|
| Present study (Huang et al.) | Taiwan (2017) | 2.4 | 14.5 | 83.0% (2–year) | 95.0% (2–year) |
| Pai et al. [ | USA (2015) | 4 | 17 | 79.2% (3–year) | 90.1% (3–year) |
| Kim et al. [ | Korea (2016) | 1.9 | 26.4 | 72.8% (4–year) | 87.7% (4–year) |
| Feroci et al. [ | Italy (2016) | 1.9 | 17 | 79.2% (3–year) | 90.2% (3–year) |
| Cho et al. [ | Korea (2012) | 1.8 | 12.2 | 81.8% (5–year) | 92.2% (5–year) |
| Park et al. [ | Korea (2015) | 2.3 | 12.0 | 81.9% (5–year) | 92.8% (5–year) |
| Ghezzi et al. [ | Brazil/Italy (2014) | 3.2 | 18.5 | 73.2% (5–year) | 85.2% (5–year) |
| Hara et al. [ | Korea (2014) | 4.5 | 10 | 81.7% (5–year) | 92.0% (5–year) |
| Bail et al. [ | Korea (2013) | 3.6 | 17.6 | 79.2% (3–year) | 93.1% (3–year) |
a TME total mesorectal excision